Abstract: The aim of the study was to demonstrate possibilities of magnetic resonance imaging (MRI) with contrast enhancement and calculation of «index of contrast agent accumulation» in diagnostics of prostate cancer. Accumulation of contrast agent in malignant and benign tissues were analyzed in comparison and in details. Efficiency of provided method of diagnosis and definition of pathologic process localization is proved. Reference 1. Franiel Т., Stephan C., Erbersdobler A., Dietz E. Maxeiner A. et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding-multiparametric MR imaging for detection and biopsy planning. Radiology. 2011; 259:162-172. 2. Kitajima K., Kaji Y, Fukabori Y, Yoshida K., Suganuma N. et al. Prostate cancer detection with 3T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J. Magn. Reson. Imaging. 2010; 31: 625-631. 3. Futterer J.J., Heijmink S.W., Scheenen T.W., Veltman J., Huisman H.J. et al. Prostate cancer localization with dynamic contrastenhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006; 241:449-458. 4. Tanimoto A., Nakashima J., Kohno H., Shinmoto H., Kuribayashi S. Prostate cancer screening: the clinical value of diffusionweighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J. Magn. Reson. Imaging. 2007; 25:146-152. 5. EL-Gabry E.A., Halpern E.J., Strup S.E., et al. Imaging prostate cancer; current and future applications. Oncology Huntingt. 2001; 15: 325-336. 6. Engelbrecht MR, Huisman HJ, Laheij R.J. MR imaging Radiology 2003; 229: 248-254. 7. Hara N., Okuizumi M. Koike H., Kawaguchi M., Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCEMRI) is a useful modality for the precise detection and staging of early prostate cancer. Eur. Radiol. 2012; 22: 746-757. 8. Nicholson B., Schaefer G., Theodorescu D. Angiogenesis in prostate cancer: biology and therapeutic opportunities. Cancer Metastasis Rev. 2001; 20: 297-319. 9. Beyersdorff D., Taupitz M., Winkelmann B. et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology. 2002; 224: 701-706. 10. Pasquier D., Hugentobler A., Masson P Which imaging methods should be used before salvage radiotherapy after prostatectomy for prostate cancer? Eur. Radiol. 2012; 22: 746-757. 11. Cirillo S., Petracchini M., Scotti L. et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur. Radiol. 2009; 19: 761-769 12. ESUR prostate MR guidelines 2012 Jelle O. Barentsz & Jonathan Richenberg & Richard Clements & Peter Choyke & Sadhna Verma & Geert Villeirs & Olivier Rouviere & Vibeke Logager & Jurgen J. F^tere^ Engelbrecht M.R., Huisman H.J., Laheij R.J., et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast enhanced MR imaging. Radiology. 2003; 229: 248-254
